EVELO BIOSCIENCES INC (EVLO) Stock Price, Quote, News and Overview
NASDAQ:EVLO - Nasdaq - US2997342025 - Common Stock - Currency: USD
EVLO Quote, Performance and Key Statistics
0.3165
-0.05 (-14.46%)
The current stock price of EVLO is 0.3165 USD. In the past month the price increased by 3.84%. In the past year, price decreased by -99.13%.
EVLO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About EVLO
Company Profile
Evelo Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Foxboro, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2018-05-09. Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The firm is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.
Company Info
EVELO BIOSCIENCES INC
124 Washington Street, Suite 101
FOXBORO MASSACHUSETTS 02139 US
CEO: Balkrishan Simba Gill
Employees: 66
Company Website: https://evelobio.com/
Phone: 16175770300
EVELO BIOSCIENCES INC / EVLO FAQ
What is the stock price of EVELO BIOSCIENCES INC today?
The current stock price of EVLO is 0.3165 USD. The price decreased by -14.46% in the last trading session.
What is the ticker symbol for EVELO BIOSCIENCES INC stock?
The exchange symbol of EVELO BIOSCIENCES INC is EVLO and it is listed on the Nasdaq exchange.
On which exchange is EVLO stock listed?
EVLO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EVELO BIOSCIENCES INC stock?
7 analysts have analysed EVLO and the average price target is 10.2 USD. This implies a price increase of 3122.75% is expected in the next year compared to the current price of 0.3165. Check the EVELO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EVELO BIOSCIENCES INC worth?
EVELO BIOSCIENCES INC (EVLO) has a market capitalization of 5.99M USD. This makes EVLO a Nano Cap stock.
How many employees does EVELO BIOSCIENCES INC have?
EVELO BIOSCIENCES INC (EVLO) currently has 66 employees.
Should I buy EVELO BIOSCIENCES INC (EVLO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EVLO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EVLO, evaluating the profitability, health, valuation and growth aspects
- EVELO BIOSCIENCES INC (EVLO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EVELO BIOSCIENCES INC (EVLO) Sales and EPS estimates to see what analysts future expectations are.
- EVELO BIOSCIENCES INC (EVLO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EVELO BIOSCIENCES INC (EVLO) Insider and Institutional Ownership to learn about the owners and their transactions.
- EVELO BIOSCIENCES INC (EVLO) Stock Chart to make your own analysis
- EVELO BIOSCIENCES INC (EVLO) Latest news and press-releases to stay up to date.
Does EVELO BIOSCIENCES INC (EVLO) stock pay dividends?
EVLO does not pay a dividend.
When does EVELO BIOSCIENCES INC (EVLO) report earnings?
EVELO BIOSCIENCES INC (EVLO) will report earnings on 2024-03-14, after the market close.
What is the Price/Earnings (PE) ratio of EVELO BIOSCIENCES INC (EVLO)?
EVELO BIOSCIENCES INC (EVLO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-29).
What is the Short Interest ratio of EVELO BIOSCIENCES INC (EVLO) stock?
The outstanding short interest for EVELO BIOSCIENCES INC (EVLO) is 0.04% of its float. Check the ownership tab for more information on the EVLO short interest.
EVLO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EVLO. When comparing the yearly performance of all stocks, EVLO is a bad performer in the overall market: 99.86% of all stocks are doing better.
EVLO Financial Highlights
Over the last trailing twelve months EVLO reported a non-GAAP Earnings per Share(EPS) of -29. The EPS decreased by -131.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -399.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EVLO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to EVLO. The Buy consensus is the average rating of analysts ratings from 7 analysts.